Subscribe
Share
Share
Embed
Welcome to EP Edge Journal Watch, where cardiac electrophysiology meets evidence, precision, and perspective.
Hosted by Dr. Niraj Sharma, this weekly podcast distills high-impact cardiovascular and Cardiac Electrophysiology and arrhythmia research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology.
What EP Edge Journal Watch stands for:
Evidence-based practice
Precision electrophysiology, arrhythmias analysis
A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings.
Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve
This program is for educational purposes only and reflects independent editorial commentary. It is not medical advice and should not replace clinical judgment or review of primary sources and guidelines. The views expressed are those of the host and contributors.
Niraj Sharma:Hello and welcome to epedge Journal Watch. I'm Doctor. Sharma. Thank you for joining me for Issue 40, our October 2026 edition. This week, we're examining 11 important research papers addressing some of the most challenging questions in clinical electrophysiology.
Niraj Sharma:Five of these papers deserve a particularly close examination. We'll begin with a question that comes up almost every day in electrophysiology practice. After successful atrial fibrillation ablation, can anticoagulation safely be discontinued? We'll look at a large observational study involving more than 13,000 patients and discuss why the answer is more complicated than the headline might suggest. Next, we'll examine a fascinating new concept called atrial fibrillation density.
Niraj Sharma:We already know that AF burden matters, but could the way episodes are distributed over time provide additional information about stroke risk? We will also evaluate the GLORIA AF stroke weighted risk score. It proposes a more refined approach to stroke prediction than conventional clinical scores, but does better statistical discrimination necessarily translate into better clinical decisions? Then we will turn to autonomic modulation, examining a randomized trial of Stellate ganglion block to prevent atrial fibrillation after coronary artery bypass surgery. And finally, we will discuss a major international study of implantable defibrillators in hypertrophic cardiomyopathy.
Niraj Sharma:This study provides an unusually long perspective on appropriate device therapies, late ventricular arrhythmias, and sudden death prevention. Along the way we will review six additional papers covering device detected atrial arrhythmias, AF progression, recurrence after ablation, omega-three fatty acids, and new approaches to Buckman bundle pacing. As always, our goal isn't simply to repeat the author's conclusions. We'll examine how the studies were designed, what the numbers actually mean, what remains uncertain, and whether the findings should influence clinical practice. Let's begin with anticoagulation after AF ablation.
Niraj Sharma:Our first featured paper is by Wren et al. Published in the Journal of the American Heart Association in 2026. The title is Thromboembolism and Bleeding Risks in Outcomes of Oral Anticoagulation after Catheter Ablation. The clinical question is familiar: a patient undergoes catheter ablation for atrial fibrillation, has an excellent procedural result, remains asymptomatic, and has no documented recurrence. At the follow-up visit, the patient asks, Do I really need to continue my blood thinner?
Niraj Sharma:Current guidelines generally recommend that long term anticoagulation decisions remain based on underlying thromboembolic risk rather than apparent ablation success. But this approach has increasingly been questioned. If ablation substantially reduces AF burden and if AF burden contributes to stroke risk, might some patients derive less benefit from continuing anticoagulation indefinitely? Ren et al. Examined this question using the prospective China AF registry.
Niraj Sharma:The analysis included thirteen thousand six hundred and sixty nine patients who underwent catheter ablation between 2011 and 2022. Patients were divided according to their anticoagulation status at six months after ablation. Two thousand six hundred and thirty seven patients continued anticoagulation. Eleven thousand and thirty two discontinued treatment. Median follow-up was four years.
Niraj Sharma:Importantly, this was not a randomized trial. The decision to continue or discontinue anticoagulation was made clinically, taking into account stroke risk, rhythm status, and physician and patient preferences. The investigators classified patients using the CHADSVA score without the sex component. Scores of zero or one were considered low risk. A score of two was intermediate risk.
Niraj Sharma:Scores of three or higher represented high risk. The outcomes included ischemic stroke or systemic embolism, major bleeding, and clinically relevant non major bleeding. The investigators used a six month landmark analysis, followed by adjusted survival models, propensity based analyses, and competing risk sensitivity analyses. This is a substantial dataset with meaningful follow-up, but as we'll see, the distinction between an observed association and a causal treatment effect is absolutely central. Now, let's examine the results.
Niraj Sharma:Among patients at low stroke risk, continued anticoagulation was associated with an adjusted hazard ratio for thromboembolism of one point one one. The 95% confidence interval extended from zero point seven zero to 1.77. Among intermediate risk patients, the adjusted hazard ratio was 0.64, with a confidence interval from 0.36 to 1.16, and among patients at high stroke risk, the adjusted hazard ratio was 1.05, with a confidence interval from 0.74 to 1.48. None of these comparisons reached conventional statistical significance. Continued anticoagulation, however, was associated with higher bleeding risk.
Niraj Sharma:Among high risk patients, the adjusted hazard ratio for major bleeding was 2.32, with a 95 confidence interval from 1.19 to 4.50. At first glance, these findings might suggest that discontinuing anticoagulation after ablation provides a favorable balance between stroke prevention and bleeding, but that would be too strong an interpretation. Consider the intermediate risk group. The hazard ratio of 0.64 suggests a possible thirty six percent lower thromboembolic hazard with continued anticoagulation, but the confidence interval extends from a potentially substantial reduction in risk to a possible increase. This result does not demonstrate that anticoagulation is ineffective.
Niraj Sharma:Likewise, in the high risk group, the confidence interval is compatible with both clinically meaningful protection and clinically meaningful harm. A non significant result is not evidence of equivalence. There is also an important treatment selection problem. Patients who remained on anticoagulation tended to be older, with higher stroke risk scores and more comorbidities. They were precisely the patients physicians believed needed anticoagulation.
Niraj Sharma:This introduces confounding by indication. Although adjustment and propensity weighting can improve balance for measured variables, they cannot reliably eliminate differences in unmeasured atrial disease, residual AF burden, or other clinical characteristics. The anticoagulant distribution is also important. Nearly forty percent of continuing patients received warfarin. Among those receiving direct oral anticoagulants, rivaroxaban and dabigatran predominated, while apixaban was uncommon.
Niraj Sharma:Consequently, we shouldn't assume that the observed bleeding profile directly represents contemporary treatment with all available direct oral anticoagulants. This paper was accompanied by an editorial from Alhassen and Kwaku entitled Anticoagulation after Atrial Toward a More Individualized Strategy. The editorial raises several important considerations: first, the absolute thromboembolic rates were relatively low, even among some patients with higher baseline stroke risk second, rhythm monitoring was intermittent. Patients underwent electrocardiograms and Holter monitoring, but the investigators did not have continuous measurements of AF burden for the entire cohort. Therefore, an absence of documented AF recurrence cannot be equated with an absence of AF.
Niraj Sharma:Third, the editorial places these results in the context of newer randomized evidence. The ALONE AF trial examined anticoagulation discontinuation in selected patients after successful ablation. The OCEAN trial examined antithrombotic treatment following successful AF ablation. And the OPTION trial addressed a different but related strategy: left atrial appendage closure compared with anticoagulation after ablation. These studies contribute to a more individualized discussion, but they don't answer exactly the same question.
Niraj Sharma:Differences in patient selection, stroke risk distribution, rhythm surveillance, treatment strategy, and endpoint definitions prevent us from treating their findings as interchangeable. There is also growing interest in rhythm guided anticoagulation, in which anticoagulant exposure is linked to continuously detected arrhythmia, but the relationship between the timing of AF and the timing of stroke is not sufficiently predictable to make this routine practice. So what's the epedge take? Ren and colleagues have identified an important question and provided substantial observational evidence, but they have not demonstrated that anticoagulation can safely be withdrawn from all patients after successful AF ablation. The clinical decision must still consider baseline stroke risk, bleeding risk, anticoagulant selection, rhythm monitoring, and patient preferences.
Niraj Sharma:In particular, the absence of statistical significance for stroke reduction does not establish that stopping anticoagulation is non inferior to continuing it. We need adequately powered randomized trials, especially in higher risk patients, using contemporary anticoagulants and more comprehensive rhythm monitoring. For now, this is evidence that should stimulate better trials and more thoughtful individualized discussions. It is not a reason to abandon guideline directed anticoagulation. Our second featured study comes from Rosman et al.
Niraj Sharma:Published in the European Heart Journal in 2026. The title is Atrial fibrillation density as a biomarker for ischemic stroke risk prediction. This is a particularly interesting paper because it questions whether our usual description of AF burden tells the whole story. Imagine two patients. Both spend twenty percent of a thirty day monitoring period in atrial fibrillation.
Niraj Sharma:The first patient has frequent short episodes scattered throughout the month. The second experiences a smaller number of prolonged episodes clustered together. Both patients have the same cumulative AF burden, but their arrhythmia patterns are quite different. The investigators asked whether that difference in temporal distribution might provide additional information about ischemic stroke risk. They refer to this characteristic as AF density.
Niraj Sharma:Density ranges from approximately zero to one. Values near zero describe more dispersed episodes. Values near one describe arrhythmia clustered into longer, more consolidated periods. The study analyzed remotely monitored device data from two large healthcare systems in The United States, the Veterans Health Administration and the University of North Carolina. From more than 41 thousand patients assessed, twelve thousand eight hundred and sixty eight met the inclusion criteria.
Niraj Sharma:Patients had implanted cardiac monitoring devices and at least one qualifying period of device detected AF. The investigators excluded permanent AF and substantial monitoring gaps. AF burden and density were assessed in thirty day intervals. Median follow-up was four years. Now one important methodological detail: the investigators didn't simply use conventional survival regression.
Niraj Sharma:They employed a statistical technique called the Parametric G formula. This approach attempts to account for variables that change over time, including anticoagulation, AF burden, physical activity, and other clinical characteristics. That's important because these variables may both influence future stroke risk and themselves be affected by earlier arrhythmia episodes. During follow-up, three thirty six patients experienced ischemic stroke. The overall observed stroke incidence was approximately six point three events per thousand person years.
Niraj Sharma:Compared with patients having low AF density, the modeled one year stroke risk increased progressively across density categories. For medium density, the adjusted risk ratio was 1.24, for medium high density it was 1.51, and for high density, the adjusted risk ratio reached 1.75 with a 95% confidence interval from 1.25 to 2.44. Importantly, the relationship persisted after accounting for total AF burden. Within comparable burden categories, patients with greater temporal concentration of AF generally had higher modeled stroke risk. In the joint analysis, the highest combination of burden and density had a risk ratio of approximately 2.02 compared with the lowest combination.
Niraj Sharma:So what should we conclude? First, AF may be more complex than simply calculating the percentage of time spent in arrhythmia. The temporal structure of that arrhythmia could carry additional prognostic information. But we need to be precise about what the statistical analysis establishes. The G formula can address measured time varying confounders under specific assumptions.
Niraj Sharma:It doesn't convert an observational study into a randomized trial. Its validity depends on accurate measurement, appropriate model specification, and adequate control of relevant confounders. There are also limitations in arrhythmia ascertainment and medication exposure. Stored electrograms were not available for independent adjudication of all device detected episodes, and anticoagulation recorded in clinical systems doesn't necessarily indicate consistent medication adherence. The epedge take is that AF density represents a meaningful conceptual advance.
Niraj Sharma:It may help identify why two patients with apparently similar AF burdens have different clinical outcomes, but there is no established AF density threshold that permits us to stop anticoagulation or initiate treatment independently of validated clinical criteria. The next step should be prospective validation, evaluation of absolute risk prediction, and eventually trials examining whether density guided management actually improves outcomes. For now density is a promising biomarker, not a treatment algorithm. Our third featured paper is by Zee and colleagues published in Europace in August 2026. The study is entitled Development and Validation of the GLORIA AF Stroke Weighted Risk Score for Patients with Atrial Fibrillation.
Niraj Sharma:Stroke prediction in AF remains challenging. The commonly used CHADS VA score, which excludes gender as a criteria, has the advantage of simplicity, but its discriminatory performance is only moderate. It also assigns equal weights to several risk factors that may not contribute equally to stroke. The investigators wanted to determine whether an interpretable weighted score could improve prediction without the complexity of more elaborate machine learning algorithms. They used the prospective multinational GLORIA AF registry.
Niraj Sharma:The original dataset contained 36,617 patients. After requiring complete baseline predictor information and follow-up, 20,517 patients remained. This distinction is important. Forty four percent of the original population was excluded because of incomplete required information. The investigators evaluated 17 candidate variables.
Niraj Sharma:They used a penalized Cox regression technique known as LASSO, combined with stability selection to identify predictors that contributed consistently to the model. 10 predictors were retained. These were converted into a weighted score ranging from zero to 23 points. Previous thromboembolism received five points, abnormal kidney function four, and age above 65.3. Hypertension, smoking history, persistent or permanent AF, and diabetes each contributed two points.
Niraj Sharma:Heart failure, coronary artery disease, and hyperlipidemia each contributed one. The model was then evaluated for discrimination, calibration, and clinical decision analytic performance. Importantly, external validation was conducted in a separate group of 8,309 patients from European and Asia Pacific AF registries, and the investigators assessed performance without refitting the original model. Let's examine the actual performance. In the derivation cohort, four eighty seven patients experienced stroke.
Niraj Sharma:The weighted GLORIA AF score achieved a C index of 0.661. The corresponding C index for CHADS VA was 0.626. The difference was statistically significant. In the independent validation cohort, the new score achieved a C index of 0.652 compared with 0.616 for the conventional score. Again, the difference was statistically significant, with a p value below 0.001.
Niraj Sharma:Now what does that mean clinically? The C index measures the ability of a model to correctly rank patients according to risk. A value of 0.5 is no better than chance. A value of one represents perfect discrimination. Improving from 0.616 to 0.652 is a real statistical improvement, but the absolute difference is only 0.036, and a C index around 0.65 still represents modest individual discrimination.
Niraj Sharma:The investigators also reported favorable calibration and improvements in reclassification measures. However, reclassification statistics can look impressive without necessarily producing better treatment decisions. There's another important limitation: nearly eighty five percent of patients in the derivation population were receiving anticoagulation at baseline. Therefore, the score largely predicts observed stroke risk in a treated population. That is not the same as predicting what their stroke risk would have been without anticoagulation.
Niraj Sharma:The investigators performed a sensitivity analysis among patients who weren't anticoagulated at baseline and the score maintained better discrimination, but this subgroup was substantially smaller. My epedge assessment is that the GLORIA AF score is a useful improvement in transparent clinical risk modeling. It demonstrates that weighting routinely available risk factors can improve discrimination, but improved prediction isn't automatically improved patient care. We need studies examining whether the score meaningfully changes anticoagulation decisions, improves net clinical benefit, and performs reliably in specific populations, including patients after catheter ablation. Until then, it should be considered a potential adjunct to establish risk assessment rather than a replacement for it.
Niraj Sharma:Before moving to AF progression, let's briefly consider another important study. Botto et al. Published a paper in Heart Rhythm in 2026 examining the association between atrial high rate episode burden and cardiovascular outcomes. This was a post hoc analysis of eleven sixty patients from the B3 pacing trial, examining whether a daily atrial high rate episode burden of at least six minutes predicted cardiovascular death, worsening heart failure hospitalization or stroke, and transient ischemic attack. Among patients without a previous diagnosis of AF, reaching this threshold was associated with an adjusted hazard ratio of approximately 4.9 for the composite outcome, although only forty seven patients in the entire analysis experienced a first composite event.
Niraj Sharma:Importantly, the association was driven primarily by heart failure hospitalization and cardiovascular death, while the stroke and transient ischemic attack comparison was not statistically significant. The epedge interpretation is that brief device detected atrial arrhythmias may indicate broader cardiovascular vulnerability, but a six minute episode is not by itself evidence that anticoagulation will improve outcomes. Two additional heart rhythm papers examined different dimensions of AF progression and recurrence. Thakur et al. Performed a systematic review and meta analysis of progression from persistent to permanent atrial fibrillation, finding a pooled rate of sixteen point four two per 100 person years across 17 contributing studies, but the heterogeneity was extreme, with an I2 of ninety eight point six percent, and greater study level exposure to pulmonary vein isolation was associated with less progression without establishing that ablation itself caused the difference.
Niraj Sharma:The important limitation is that permanent AF is partly a clinical designation reflecting the decision to stop pursuing rhythm control, not simply a biological stage of disease. Chen et al. Examined clinical risk factors for arrhythmia recurrence after AF ablation in 152 prospective studies involving nearly fifty thousand patients. Smoking, periodontitis, metabolic syndrome, sleep apnea, and persistent AF were associated with recurrence, while untreated sleep apnea carried an adjusted hazard ratio of approx. Two point four one.
Niraj Sharma:These findings reinforce the importance of systematic risk factor assessment, although they don't prove that modifying each associated factor will necessarily produce a corresponding reduction in recurrence. Taken together, these papers remind us that AF progression and post ablation recurrence are related but different endpoints and both require careful interpretation. Our fourth featured paper comes from Tian et al. Published in JACC Clinical Electrophysiology in 2026. The title is Stellate ganglion block reduces the incidence of postoperative atrial fibrillation after coronary artery bypass grafting.
Niraj Sharma:This is particularly interesting because unlike the preceding observational analyses, this was a randomized intervention study. Postoperative atrial fibrillation is common following cardiac surgery. Sympathetic activation, inflammation, myocardial injury, and atrial stretch all contribute to the underlying vulnerability. The investigators asked whether temporary interruption of left sided sympathetic activity before coronary bypass surgery could reduce postoperative AF. They randomized 124 patients to receive an ultrasound guided left stellate ganglion block or usual care without the block.
Niraj Sharma:The procedure was performed after induction of general anesthesia before surgery. The primary endpoint was AF, occurring during the first five postoperative days. Rhythm was evaluated using continuous telemetry and daily electrocardiograms. The modified intention to treat population included 108 patients, 54 in each treatment group. The per protocol population was smaller, at 98 patients.
Niraj Sharma:This deserves attention because patients excluded after randomization can potentially weaken the protections created by random treatment allocation. Baseline beta blocker use was similar between groups. Approximately sixty nine percent of patients in each group were receiving beta blockers. Postoperative treatment for AF included amiodarone and, when appropriate, esmolol or electrical cardioversion. This is important because the intervention was tested in the context of other perioperative treatments rather than in their absence.
Niraj Sharma:The study therefore addresses whether stellate ganglion block can add benefit to existing perioperative care. The primary result was striking. Postoperative AF occurred in ten of fifty four patients receiving stellate ganglion block or eighteen point five percent. In the control group, it occurred in twenty four of fifty four patients, or forty four point four percent. The reported odds ratio was zero point two eight eight, with a 95% confidence interval from 0.106 to 0.731.
Niraj Sharma:The p value was 0.007. Now let's translate that into clinically meaningful terms. The absolute difference in AF incidence was approximately twenty five point nine percentage points. The observed relative risk was approximately zero point four two, and the inverse of the absolute risk reduction gives an exploratory number needed to treat of approximately four. In other words, within this study population, roughly four patients would need receive the intervention to prevent one episode of postoperative AF during the five day observation period.
Niraj Sharma:That's a substantial effect. But the number needed to treat is a point estimate from a small study, not a validated universal treatment estimate. The investigators also found lower AF burden, shorter episodes, fewer antiarrhythmic treatments, and a shorter postoperative hospital stay. Median duration of the first AF episode was fifteen point five hours with the block, compared with forty two hours in controls. No block related complications were reported, but we should be careful about interpreting safety from such a small sample.
Niraj Sharma:The absence of observed complications doesn't establish that the intervention is risk free. And there are several methodological concerns. The study was conducted at a single center. There was no sham block. 16 randomized patients were not included in the modified intention to treat population.
Niraj Sharma:Numerous secondary endpoints and exploratory subgroup comparisons were evaluated. The study was also limited to early postoperative AF rather than long term rhythm outcomes, stroke, or mortality. The EP EDGE take is that this is a promising randomized signal. It suggests that autonomic modulation may influence the early postoperative atrial arrhythmia substrate, but I wouldn't recommend routine prophylactic stellate ganglion block on the basis of this study alone. We need larger multicenter trials, preferably with sham controls, rigorous intention to treat analysis, standardized co interventions and longer follow-up.
Niraj Sharma:The important question now is whether this substantial early reduction is reproducible and whether it improves outcomes that matter to patients. Now let's turn briefly to another potentially modifiable contributor to atrial fibrillation. Abhakneisha and colleagues published an updated meta analysis in Arrhythmia and Electrophysiology in 2026, examining omega-three fatty acid supplementation and new onset AF. The analysis included 35 randomized trials and more than 114,000 participants, stratified by cardiovascular risk and daily omega-three dose. In patients at high cardiovascular risk receiving more than fifteen hundred mg per day, treatment was associated with increased AF, with a pooled odds ratio of one point four three and an absolute risk difference of approximately zero point eight percentage points.
Niraj Sharma:Other dose risk combinations did not demonstrate statistically significant increases, although differences in AF ascertainment formulation and available event data prevent concluding that all lower dose exposure is necessarily without risk. The epedge assessment is that this finding supports individualized discussion of arrhythmia risk when prescribing high dose omega-three therapy balanced against the proven cardiovascular benefits of the specific product and indication. Two smaller studies examine an interesting direction in physiological atrial pacing. First, Mullier et al. Published a Europace study evaluating whether a posterior electrocardiographic lead (V8) could provide a non invasive measurement of left atrial activation during Buckman bundle pacing.
Niraj Sharma:In two prospective cohorts of 50 patients each, the V eight P wave downslope measurement correlated strongly with invasive coronary sinus activation, with a correlation coefficient of approximately 0.94, Buchmann bundle pacing, shortened activation measurements and corrected partial interatrial block in twenty of twenty three affected patients. However, the Bland Altman agreement limits were approximately plus or minus 22 ms, reminding us that strong correlation doesn't necessarily imply perfect individual measurement agreement. Second, Harris and colleagues published a five patient feasibility series in the Journal of Cardiovascular Electrophysiology, using electroanatomic mapping and intracardiac ultrasound to guide leadless atrial pacemaker implantation near the Bachmann bundle. Successful fixation was achieved in four patients while one required right atrial appendage placement because of elevated thresholds. The epedge take is that these studies provide complementary evidence about physiological atrial activation and the feasibility of a new implantation approach, but neither establishes improved long term AF, heart failure, or survival outcomes.
Niraj Sharma:Our fifth and final featured paper comes from Rowan et al. Published in Circulation on 10/06/2026. The title is International Experience with Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High Risk Patients with hypertrophic cardiomyopathy. This is a large international multicenter study examining the long term experience with implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. The investigators examined records from 25 specialist centers across multiple continents.
Niraj Sharma:They included three thousand three hundred and eighty seven patients who received ICDs between 1992 and 2024. Of these, three thousand one hundred and forty underwent implantation for primary prevention, two forty seven received ICDs for secondary prevention. Mean follow-up was approximately seven years, with some patients followed for as long as thirty two years. The investigators examined appropriate ICD interventions, clinical predictors of ventricular arrhythmias, device complications, and mortality. An appropriate intervention was defined by documented ventricular fibrillation, polymorphic ventricular tachycardia, or sustained rapid monomorphic ventricular tachycardia treated by the device.
Niraj Sharma:This distinction is important. The investigators weren't merely counting shocks, they included appropriate anti tachycardia pacing and defibrillation therapies with intracardiac electrogram review. The study also evaluated established sudden death risk markers including unexplained syncope, non sustained ventricular tachycardia, left ventricular apex aneurysm, systolic dysfunction, extensive hypertrophy and other clinical characteristics. Unlike a randomized trial, patients entered the study because clinicians had already selected them for ICD therapy. That makes the population particularly informative about long term outcomes after implantation, but it also limits what we can conclude about the causal benefit of implantation compared with no ICD.
Niraj Sharma:Now let's examine the results. Among all three thousand three hundred and eighty seven patients, five fifty experienced at least one appropriate ICD intervention. That s sixteen percent overall. Among patients implanted for primary prevention, four sixty four of three thousand one hundred and forty received appropriate therapy. That's approximately fifteen percent with an annual rate of about two point two percent.
Niraj Sharma:Among secondary prevention patients, eighty six of two forty seven received appropriate therapy or thirty five percent. The annual rate in that group was approximately six point four percent, but one of the most interesting findings concerns the timing of these interventions. Among primary prevention recipients who experienced appropriate ICD therapy, the median time to first intervention was four years, sixteen percent received their first appropriate therapy at least ten years after implantation, and nearly half of those receiving appropriate therapy experienced multiple discrete interventions. These findings emphasize that ventricular arrhythmic vulnerability can persist for many years. They also have implications for counseling patients about long term device management and generator replacement.
Niraj Sharma:Another important finding was the low observed rate of sudden death. Among primary prevention recipients, eleven patients (approximately zero point four percent ) died suddenly. Ten year survival free from hypertrophic cardiomyopathy related mortality was approximately ninety seven percent. At twenty years, it was approximately ninety one percent. Risk markers associated with appropriate intervention included unexplained syncope, left ventricular apex aneurysm, reduced systolic function, and non sustained ventricular tachycardia.
Niraj Sharma:Now, there is an important statistical distinction. An appropriate ICD intervention does not automatically mean that the patient would otherwise have died. Some ventricular tachycardias might have terminated spontaneously or remained hemodynamically tolerated. Conversely, successful termination of ventricular fibrillation provides compelling evidence that the device treated a potentially fatal rhythm. We cannot simply count every appropriate intervention as one sudden death prevented.
Niraj Sharma:There is no comparable untreated control group, and patients were selected for implantation based on clinical risk. Therefore, the study cannot directly estimate the absolute mortality reduction caused by ICD therapy. The epedge take is that these data provide substantial support for the long term effectiveness and durability of appropriate ICD therapy in selected patients with hypertrophic cardiomyopathy, but they reinforce the need for individualized risk assessment rather than universal implantation. We must continue to weigh arrhythmic vulnerability, competing causes of death, device complications, inappropriate therapies, and patient preferences. The most important message may be that the risk horizon in hypertrophic cardiomyopathy extends well beyond the first few years after diagnosis or implantation.
Niraj Sharma:As we conclude issue 40, let's bring the evidence together. Ren and colleagues remind us that anticoagulation decisions after AF ablation remain more complicated than simply documenting sinus rhythm. Their observational findings raise important questions, but don't establish that discontinuation is safe across all stroke risk groups. Roseman et al. Introduced AF density as an additional dimension of arrhythmia characterization, suggesting that the temporal distribution of AF may matter beyond total burden.
Niraj Sharma:The GLORIA AF weighted score offers statistically better stroke discrimination than conventional scoring, although we still need evidence that this improvement translates into better treatment decisions. The randomized Stellate ganglion block study suggests a substantial reduction in early postoperative AF, but larger trials are needed before incorporating the procedure into routine preventive care. And the International hypertrophic cardiomyopathy experience demonstrates the long term frequency of appropriate interventions, including events occurring more than a decade after implantation. The additional studies reinforce the importance of AF progression, modifiable clinical risk factors, appropriate interpretation of device detected arrhythmias, the cardiovascular context of omega-three therapy, and the emerging possibilities of physiological atrial pacing. Perhaps the common theme is that better measurement does not automatically mean better treatment.
Niraj Sharma:Whether we're measuring AF density, clinical risk scores, activation timing, or defibrillator interventions, the challenge is knowing which measurements are reliable, clinically meaningful, and actionable. That's where careful interpretation of methods, absolute risk, confidence intervals and study limitations remains essential. You can find the accompanying epedge journal watch newsletter, detailed analyses, graphics and full article references on LinkedIn and at epedge.substack.com. And remember our website, epedge.org and its convenient app, will be coming soon. If you found this discussion useful, please consider following the newsletter, subscribing to the podcast, and sharing the episode with colleagues who may find the evidence relevant.
Niraj Sharma:Questions, suggestions, or concerns can be emailed to epedge Cast@gmail . com. Thank you again for joining me. I am Doctor. Sharma and this has been epedge journal watch.
Niraj Sharma:Until next time, bye and take care.